Revenue, 2025

USD 5.82 Billion

Forecast, 2035

USD 10.82 Billion

CAGR, 2026-2035

6.4%

Report Coverage

United States

U.S. Intravenous Solutions Market Trends for 2026

The U.S. intravenous solutions market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.19 billion in 2026 to approximately USD 10.82 billion by 2035, expanding at a CAGR of 6.4% from 2026 to 2035. The U.S. intravenous solutions market is growing because of the rising prevalence of chronic and acute health diseases that need fluid therapy, boosted by technological development and increasing healthcare infrastructure.

Key Takeaways

• United States intravenous solutions market to crossed USD 6.19 billion by 2026.
• Market projected at USD 10.82 billion by 2035.
• CAGR of 6.4% expected in between 2026 to 2035.
• By product type, the crystalloids segment held 72% market share in 2025.
• By product type, the colloids segment held the second-largest market share of 28% in 2025, and is expected to grow at the fastest CAGR of 7.0% during the forecast period.
• By nutritional content, the non-nutritional IV solutions segment held the largest market share of 68% in 2025.
• By nutritional content, the parenteral nutrition solutions segment held a significant market share of 32% in 2025, and is expected to grow at the fastest CAGR of 7.3% during the forecast period.
• By volume, the large volume parenterals (LVP) segment held the largest U.S. intravenous solutions market share of 64% in 2025.
• By volume, the small volume parenterals (SVP) segment held a notable market share of 36% in 2025, and is expected to grow at the fastest CAGR of 6.8% during the forecast period.
• By end user, the hospitals segment held the largest market share of 58% in 2025.
• By end user, the ambulatory surgical centers (ASCs) segment held a notable market share of 14% in 2025, and is expected to grow at the fastest CAGR of 7.1% during the forecast period.

Market Overview: What are Intravenous Solutions?

The U.S. intravenous solutions market is growing, as IV fluids are particularly formulated liquids that are injected into a vein to avoid or manage dehydration. They are applicable to patients of various ages who are injured, sick, dehydrated from a workout or heat, or suffering from surgery. IV fluids are liquids injected into an individual’s veins via an IV tube. IV fluids are also applied specifically to treat an emerging electrolyte or acid-base disorder. IV fluids are significant in the management of certain subtypes of hypernatremia, hyponatremia, metabolic alkalosis, and metabolic acidosis. IV fluid restores fluid to the intravascular space, and IV fluids are applied to enable the movement of fluid among compartments due to osmosis.

How is AI governing the U.S. Intravenous Solutions Market?

AI-driven technology is increasingly playing an important role in different aspects of medical care, involving infusion therapy. Intravenous therapy includes the administration of medications, fluids, or nutrients via an intravenous (IV) line, and AI-based technology improves safety, effectiveness, and patient results. An AI-based algorithm is responsible for processing the sensor data in real-time. It is trained to recognize patterns and irregularities related to blood backflow actions. This training includes a dataset of known backflow events and non-events. An AI-driven auto-shutoff mechanism would engage with different functions of IV services.

Future Outlook Trends in the U.S. Intravenous Solutions Market

• Shift to Home Healthcare: Increasing shift to home healthcare from inpatient services, including enhanced well-being and lowered readmission rates. It saves them from needless visits to the hospital by providing access to video consults and at-home nurses.
• Specialized Nutrition: Specialized nutrition, such as IV vitamin therapy, offers an energy boost by replenishing significant vitamins and minerals, such as B-complex vitamins and magnesium. This supports reducing fatigue, enhancing mental clarity, and improving overall vitality.
• Smart Infusion Technology: The advent of smart infusion pumps allowable for healthcare decision support tools to be integrated into the medication administration technology. Infusion pumps involve precision, alerts, KVO, pressure control, and various advantages.

Quick Facts Table

Segmentation Analysis

By Product Type Insights

Crystalloids Segment Led the U.S. Intravenous Solutions Market in 2025

The crystalloids segment contributed the largest market share of 72% in 2025, as crystalloids are most often preferred because of their ease of administration and reduced challenges of allergic reactions. These fluids are further classified on the basis of their electrolyte composition, osmolarity, and metabolic properties. They are applied for growing the intravascular volume in conditions such as dehydration, hypotension, and sepsis.

The colloids segment held the second-largest share of 28%, and is expected to grow at the fastest CAGR of 7.0% in the market, as colloids have larger molecules, are affordable, and also provide swifter volume increase in the intravascular space.  Colloids are better than crystalloids at escalating the circulatory volume, because their larger molecules are retained more simply.

By Nutritional Content Insights

Non-nutritional IV Solutions Segment Led the U.S. Intravenous Solutions Market in 2025

The non-nutritional IV solutions segment contributed the largest market share of 68%, as it offers subjective developments in energy levels, mental clarity, and overall well-being following administration. It provides rapid recovery from conditions like dehydration, hangovers, jet lag, and physical exhaustion when managed with IV fluids improved with electrolytes, B vitamins, and vitamin C.

The parenteral nutrition solutions segment held a significant share of 32% of the market in 2025. Parenteral nutrition is the ability to help patients who can’t eat or absorb nutrients via conventional means. It allows nutritional services to be infused for 8 to 18 hours daily. It provides satisfactory nutrients in the face of gastrointestinal dysfunction.

By Volume Insights

The Large Volume Parenterals (LVP) Segment held the Largest Share in the Market in 2025

The large volume parenterals (LVP) segment contributed the largest U.S. intravenous solutions market share of 64% in 2025, as it is a single-dose injection that is designed for intravenous applications and is packaged in containers labelled as containing more than 100 mL. It is applied to offer fluids, electrolytes, and nutrition intravenously. These solutions in either the plastic bag or the glass bottle flow from the containers to the patient via an administration set.

The small volume parenterals (SVP) segment held a notable share of 36% of the market in 2025, expected to grow at the fastest CAGR of 6.8% of the market, as small volume parenterals have volumes less than 100mL and involve solutions, emulsions, suspensions, and dry powders. It is packaged in various ways based on the intended use.

By End User Insights

The Hospitals Segment held the Largest Share in the Market in 2025

The hospitals segment contributed the largest U.S. intravenous solutions market share of 58% in 2025, as in hospital applicable to manage pain and nausea by rapidly achieving therapeutic levels, and they are more reliably and completely absorbed compared with medications given by various routes of injection. IV infusion therapy delivers blood, fluids, nutrients, and medication directly to the bloodstream to supports to feel better rapidly.

The ambulatory surgical centers (ASCs) segment held the second largest share of 14%, and is expected to grow at the fastest CAGR of 7.1% of the market, as ambulatory infusion centers offer optimum services for field physicians committed to bringing timely, efficient treatments. It is making treatments more effective and patient-friendly. It provides comfortable treatment environments with private or semi-private rooms.

The clinics segment held a notable share of 11% the market, as IV therapy use in clinics delivers fluids straight to the bloodstream, offering rapid and efficient hydration that helps significant organ function and supports to feel better almost rapidly.

The home healthcare segment held a notable share of 10% of the U.S. intravenous solutions market. Home infusion therapy reduces travel expenses, lowers hospital admissions, and limits the likelihood of hospital-acquired infections, eventually creating more positive patient results. Home infusion therapy enhances end-of-life care by increasing the time patients spend with their family at home.

Supply Chain Analysis

R&D:

• Research and development (R&D) in intravenous solutions includes a rigorous process focused on design stability, sterilization validation, container compatibility, and government compliance to ensure efficacy and safety.
• Key Players: Pfizer Inc. and Grifols, S.A. 

Manufacturing Processes:

• The manufacturing processes for intravenous solutions involve water purification, mixing ingredients, microfiltration, sterile container forming and filling, terminal sterilization, and advanced quality control testing.
• Key Players: Baxter International Inc. and ICU Medical, Inc.

Patient Services:

• Patient services in intravenous (IV) solution therapy include the administration of fluids, electrolytes, medications, or nutrients directly into the bloodstream to manage dehydration, shock, or metabolic inequities
• Key Players: B. Braun Medical Inc. and Fresenius Kabi USA

Latest Updates of Key Players in the U.S. Intravenous Solutions Market

SWOT Analysis

Strengths

• Intravenous medications deliver an instant, fast-acting therapeutic effect, which is important in emergent situations, like cardiac arrest or narcotic overdose.
• IV infusion therapy brings fluids, blood, nutrients, and medication directly to the bloodstream to supports feel better instantly.

Weakness

• Excessive fluid administration causes pulmonary and peripheral edema, specifically in patients with pre-existing heart or renal disease, important to higher mortality.

Opportunities

• IoT-driven smart saline bottle intended to improve patient safety and healthcare effectiveness. The proposed system integrates sensors, microcontrollers, and wireless communication to incessantly monitor saline levels
• IV drug delivery provides unparalleled speed and accuracy. Medications delivered intravenously reach their target rapidly. This makes it the preferred process for drugs that need immediate action, such as emergency medications and anaesthesia.

Threat

• Growing IV related difficulties, such as phlebitis, infiltration, extravasation, and infection, delay treatment, prolong hospitalization, and increase medical care.

Recent Developments in the U.S. Intravenous Solutions Market

• In November 2025, Solventum announced it had entered into a definitive agreement to acquire Acera Surgical, a confidentially held bioscience organization focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.
• In May 2025, ICU Medical Inc. and Otsuka Pharmaceutical Factory, Inc. (OPF), announced the formation of Otsuka ICU Medical LLC, a novel joint venture with the goal of strengthening the IV solutions supply chain
• In April 2025, Organon, a worldwide healthcare organization with a deep expertise in biosimilars, announced that it had acquired from Biogen Inc. regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, for intravenous infusion.
• In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that have demonstrated promising initial clinical activity. The EsoBiotec Engineered NanoBody Lentiviral platform authorizes the immune system.

Segments Covered in the Report

By Product Type

• Crystalloids
  • Normal Saline
  • Lactated Ringer’s Solution
  • Dextrose Solutions
    • D5W
    • D10W
  • Others 
• Colloids
  • Albumin Solutions
  • Hydroxyethyl Starch (HES)
  • Gelatin-based Solutions
  • Dextran Solutions

By Nutritional Content

• Parenteral Nutrition Solutions 
  • Total Parenteral Nutrition (TPN)
  • Peripheral Parenteral Nutrition (PPN)
• Non-nutritional IV Solutions

By Volume

• Small Volume Parenterals (SVP)
  • ≤100 ml
• Large Volume Parenterals (LVP)
  • 100 ml

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Plastic Bottles

By Packaging Type

• Flexible Bags
• Glass Bottles
• Plastic Bottles

By Distribution Channel

• Direct Sales
• Group Purchasing Organizations (GPOs)
• Retail & Online Pharmacies